J
Juliann Chmielecki
Researcher at AstraZeneca
Publications - 124
Citations - 16230
Juliann Chmielecki is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 45, co-authored 117 publications receiving 12742 citations. Previous affiliations of Juliann Chmielecki include Massachusetts Institute of Technology & Broad Institute.
Papers
More filters
Journal ArticleDOI
Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant.
Christine A. Parachoniak,Andrew Rankin,Bernadette Gaffney,Ryan J. Hartmaier,Dan Spritz,Rachel L. Erlich,Vincent A. Miller,Deborah Morosini,Phil Stephens,Jeffrey S. Ross,John Keech,Juliann Chmielecki +11 more
TL;DR: A near-complete and ongoing 14-mo response to everolimus therapy of a heavily pretreated patient with biphenotypic, metastatic breast cancer is reported, suggesting further investigation of this variant is warranted to better understand its role as a potential biomarker for mTOR inhibitor sensitivity in the appropriate clinical context.
Journal ArticleDOI
EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib
Juliann Chmielecki,M. Catherine Pietanza,Dana T. Aftab,Ronglai Shen,Zhiguo Zhao,Xi Chen,Katherine E. Hutchinson,Agnes Viale,Mark G. Kris,Thomas J. Stout,Vincent A. Miller,Naiyer A. Rizvi,William Pao +12 more
TL;DR: The results of this exploratory study raise the possibility that different EGFR TKIs could be sequentially used to improve outcomes in patients with EGFR-mutant lung cancer.
Journal ArticleDOI
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
Kathleen N. Moore,Setsuko K. Chambers,Erika Hamilton,Lee-may Chen,Amit M. Oza,Sharad A. Ghamande,Gottfried E. Konecny,Steven C. Plaxe,Daniel Lewis Spitz,Jill J.J. Geenen,Tiffany A. Troso-Sandoval,Janiel M. Cragun,Esteban Rodrigo Imedio,Sanjeev Kumar,Ganesh Mugundu,Zhongwu Lai,Juliann Chmielecki,Suzanne F. Jones,David R. Spigel,Karen Cadoo +19 more
TL;DR: Adavosertib, a highly selective WEE1 inhibitor, demonstrated activity and tolerability in combination with carboplatin in primary PROC using NCT02272790.5513.
Journal ArticleDOI
Identifying ALK rearrangements that are not detected by FISH with targeted next-generation sequencing of lung carcinoma.
Siraj M. Ali,Sai-Hong Ignatius Ou,Jie He,Nir Peled,Juliann Chmielecki,Mary Colleen Pinder,Norma Alonzo Palma,Wallace Akerley,Kai Wang,Julian R. Molina,Jeffrey S. Ross,Roman Yelensky,Garrett M. Frampton,Lyudmila Bazhenova,Gary A. Palmer,Deborah Morosini,Doron Lipson,Phil Stephens,Ravi Salgia,Vincent A. Miller +19 more
TL;DR: Genomic rearrangements of ALK are the defining feature of a subset of lung non-small cell carcinomas (NSCLC), and predict response to ALK-targeted therapies, and are reviewed in detail.
Proceedings ArticleDOI
Abstract CT025: Phase Ib study of adavosertib in combination with olaparib in patients with refractory solid tumors: Dose escalation
Erika Hamilton,Gerald Steven Falchook,Judy Wang,Siqing Fu,Amit M. Oza,So Karen,Esteban Rodrigo Imedio,Sanjeev Kumar,Lone Ottesen,Ganesh Mugundu,Juliann Chmielecki,Suzanne F. Jones,David R. Spigel,Bob T. Li +13 more
TL;DR: Treatment with adavosertib in combination with olaparib in patients with refractory solid tumors showed antitumor activity, mostly at the MTD/RP2D for the BID schedule, which was determined to be adavoertib 175 mg (3/4) for 2/3 weeks plus olapalib 200 mg BID.